A San Diego biotech looking to double up on the power of antibody-drug conjugates with fewer toxicities has patched together a $137 million Series B from a group of blue-chip investors. The seven-employee startup, called Sidewinder Therapeutics, plans to make its mark by simultaneously engaging two targets and “overcoming fundamental limitations in the first-gen ADCs,” CEO Eric Murphy said in an interview. That includes avoiding off-target toxicities that arise when ADC payloads spill into the b

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. April 07, 2026 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (rem

First-in-class TET2 activator targets DNA damage response in GBM and other cancers Strong preclinical efficacy, brain penetration, and safety pro clinical advancement Study led by world-leading glioblastoma investigators, including Dr. Roger Stupp Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and ot

April 7, 2026 -- ATLATL Innovation Center (hereinafter referred to as "ATLATL"), a global innovation platform for life science research and development, announced an agreement with Daiichi Sankyo to leverage ATLATL's multi-regional innovative R&D network and expertise in the Asia-Pacific biotech sector to help Daiichi Sankyo identify high-quality R&D platform technologies and accelerate the transformation and implementation of innovative science in order to potentially bring new treatment option

It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for recent examples). Aashish Manglik But two cancer biologists — Aaron Ring at the Fred Hutchinson Cancer Center and Aashish Manglik at UCSF — believed they could go one layer deeper than others. Even within a single protein target, there could be different ways for a drug to attach. They just needed a systematic way to seek out those small bits on a pr

An investigational medicine that addresses the genetic root cause of BAG3 DCM, AFTX-201 is being evaluated as a treatment for BAG3 DCM in the UPBEAT trial in the U.S. and Canada AFTX-201 is designed using Affinia’s proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than doses of gene therapies using conventional capsids Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno

VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont) Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040s Neurocrine to H

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction in Proptosis; Greater Than 3 mm April 6, 2026 -- Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED). TEPEZZA OBI provides comparable

Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity over the KAT5 and KAT8 paralogs KAT6/7 dual inhibitor demonstrates greater monotherapy efficacy and durability than KAT6 selective inhibitors in preclinical CDX and PDX models Multiple combination opportunities with IDE574 and IDEAYA's proprietary pipeline Potential first-in-clas

Liechtenstein-based biotech company reports significant lifespan extension in C. elegans and advances toward preclinical development with CRO partners April 3, 2026 -- Virella Ltd, a European biotech company developing small-molecule SIRT6 activators, has filed a European Patent Application covering its proprietary compound series targeting the Sirtuin 6 enzyme. The filing marks a key milestone as the company advances toward preclinical studies with contract research partners.SIRT6 is an NAD+-d